TG Therapeutics Reports Q2 2026 Financial Results and Raises BRIUMVI Revenue Guidance
TG Therapeutics reported Q2 2026 total global revenue of approximately $240 million, exceeding its guidance. The company raised its full year financial targets as BRIUMVI commercial performance continues to outperform expectations.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day